Recursion Pharmaceuticals · conference-presentation
Recursion Pharmaceuticals | Investor Day Presentation Deck | 143 slides
120 pages · 3 arc beats · 3 loops
Recursion Pharmaceuticals | Investor Day Presentation Deck | 143 slides
Recursion Pharmaceuticals · 2023-01 arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
15101520253035404550556065707580859095100105110115120
Deck intelligence map
3 coverage by narrative range · generated from this deck JSON
Narrative range 114 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem (Identify pain) 3 slides 100% 3/3 slides 100% 3/3 slides · 15 hits — 0/3 slides
100% 3/3 slides · 5 hits 100% 3/3 slides · 4 hits 100% 3/3 slides 100% 3/3 slides Agitate (Make it worse) 5 slides 100% 5/5 slides 100% 5/5 slides · 19 hits — 0/5 slides
40% 2/5 slides 60% 3/5 slides 100% 5/5 slides 100% 5/5 slides Solution (Provide relief) 106 slides 100% 106/106 slides 100% 106/106 slides · 451 hits — 0/106 slides
44.3% 47/106 slides · 52 hits 40.6% 43/106 slides 100% 106/106 slides 100% 106/106 slides · 112 hits Slide inventory
120 every slide · same image gating as the playbook
07
The chart uses a logarithmic scale on the y-axis to show the exponential decay of efficiency over time.diagnose_problem
08
The slide highlights the divergence between technological progress in computing and the stagnation in pharmaceutical R&D productivity.frame_problem
09
The slide uses a classic 'before-after' or 'gap' framing by contrasting two opposing trends to justify the company's existence.frame_problem
10
The slide uses a personal/inspirational photo to set the stage for a scientific hypothesis.frame_problem
11
The slide uses a personal/foundational anecdote to introduce a core business hypothesis.establish_context
12
The slide uses a linear process flow to represent the drug discovery pipeline.present_framework
13
The slide uses a circular, iterative process flow overlaid on a background representing different technology layers.present_framework
14
Uses a funnel diagram to illustrate process optimization.present_solution
15
The slide uses a funnel-style comparison for attrition rates, followed by two bar charts for cost and time.analyze_data
17
The chart uses a 2x2 matrix structure to map competitive positioning.compare_peers
19
The visual on the right is a complex node-link diagram representing biological data.establish_context
20
The slide uses a purple gradient overlay on a photo mosaic to create a cohesive visual theme.transition
23
The slide uses a process-oriented diagram to map stages (Inference, Hit to Lead, Lead Optimization, Candidate Evaluation, IND Preparation) to underlying technolpresent_framework
24
The background features a complex network graph visualization.summarize
25
The image shows a fluorescent microscopy view of neurons.establish_context
28
The slide uses a street-view image as a metaphor for 'mapping' or 'connectivity'.present_framework
30
The diagram uses a hub-and-spoke style visualization where 'Breast Cancer' is the central node connected to a subset of genes, while others are peripheral.analyze_data
31
The diagram uses a chord-like visualization to map gene associations to a central Breast Cancer node.analyze_data
32
The diagram uses a hub-and-spoke style layout with Breast Cancer as the central node.other
33
The diagram uses a circular layout with nodes on the perimeter and connecting arcs representing relationships. Labels include gene names (e.g., KRAS, NRAS, BRAFanalyze_data
34
This is a chord diagram or similar flow visualization, often used to show relationships between entities.other
35
The diagram uses a hub-and-spoke visual metaphor to show many-to-one screening.frame_problem
36
The diagram resembles a neural network or a complex mapping process.present_framework
37
The diagram uses a series of overlapping circles to represent stages of drug discovery, connected to specific technological capabilities (Phenomics, Transcriptopresent_framework
38
The slide uses a process-flow icon at the top to indicate the 'Hit ID' stage of a drug discovery pipeline.present_framework
39
The slide uses a Venn-like overlapping pill shape to show how specific data modalities (Phenomics, Transcriptomics, etc.) feed into different stages of the drugpresent_framework
40
The slide illustrates a drug discovery pipeline workflow.present_framework
41
The slide uses a funnel-like progression visual to show how different technologies (Phenomics, Transcriptomics, InVivomics) integrate into the drug discovery prpresent_solution
42
The slide uses a before-after framing to contrast manual/mechanical observation with automated digital tracking.present_solution
43
The slide uses a before-after framing to contrast traditional manual rotarod assays with high-throughput digital phenotyping.compare_peers
44
The slide uses a comparison frame to highlight speed advantages.compare_peers
45
The slide uses a layered circular process flow diagram to represent the progression of drug discovery stages.present_solution
46
The DMTA cycle is represented as a circular process flow.present_solution
47
Includes a process flow diagram at the top and specific performance metrics for chemical algorithms.present_solution
48
The slide features a technical diagram of a DeBERTa-based architecture for chemistry and biology pre-training.present_solution
49
The slide features a process flow diagram at the top right and a photo of the Biosero robotic system.present_solution
50
Includes a process flow icon at the top right indicating the stage of the drug discovery pipeline.present_solution
51
The diagram uses a layered stack to represent data integration, connected by nodes.present_framework
53
The heatmap shows a diagonal of high correlation (red) and various clusters of gene interactions.present_framework
54
The heatmap likely represents a correlation matrix or gene-gene interaction map. The slide uses a two-column layout to categorize capabilities.present_framework
55
The image on the right is a network graph visualization, likely representing protein-protein interactions or molecular pathways.establish_context
56
The slide uses a before-after framing to contrast the current market reality with the desired therapeutic outcome.frame_problem
57
The slide outlines a drug discovery workflow from target identification to preclinical validation.present_solution
58
The slide uses a 'problem-solution' structure, contrasting the high unmet need in cancer patients (left) with the efficacy of the REC-0648918 compound in mouse analyze_data
59
The slide uses a 'problem-solution' structure, contrasting market statistics with experimental dot plots.diagnose_problem
60
The slide uses a problem-solution structure, contrasting market statistics with experimental cytokine data.diagnose_problem
61
The slide uses a problem-solution framing: the left side establishes the market problem (low efficacy/high toxicity), and the right side presents pre-clinical ddiagnose_problem
62
The slide uses a process-oriented layout to explain how medicinal chemistry efforts are informed by assay data.present_framework
63
The slide highlights a specific subset of data (Compound 2A/2B) where phenomics shows a dramatic improvement, suggesting a redirection of chemistry efforts.analyze_data
64
The slide contrasts standard dose-response curves (univariate) with a phenotypic similarity matrix (heatmap) to highlight the value of phenomics in drug discoveanalyze_data
65
The slide uses a heatmap to visualize phenotypic similarity/clustering, highlighting the 'Target Phenotype' vs 'Compound 2A' (CDK9).diagnose_problem
66
The slide uses heatmaps to visualize gene-gene and compound-phenotype correlations, highlighting the platform's ability to identify specific biological relationillustrate_case
67
The image on the right is a network graph, likely representing protein-protein interactions or a biological pathway map.establish_context
68
The slide uses a decision tree/flowchart to segment patient populations by biomarker status and show corresponding mPFS outcomes.diagnose_problem
69
The heatmap illustrates the similarity of the drug REC-65029 at various concentrations to the targets CDK12, RBM39, and CDK13.present_solution
70
The slide uses two line charts to demonstrate efficacy. The top banner indicates the context is HR-proficient ovarian cancer PDX.analyze_data
71
The slide uses a numbered list format to present three distinct experimental outcomes, each supported by a time-series chart of daily motion.summarize
72
The slide uses a process diagram to illustrate the drug discovery pipeline integrated with various omics and predictive technologies.plan_implementation
75
Uses a pyramid-like structure to represent data hierarchy and a callout to highlight the specific subset.establish_context
76
The slide contains three distinct chart types: a line chart for cell count impact, a statistical significance plot, and a grid of cosine similarity concentratioillustrate_case
77
The heatmap displays gene expression or similarity data across different concentrations of EW-719.analyze_data
78
The pyramid represents the 'Recursion Data Universe' (>21 PB).analyze_data
81
The slide uses a hub-and-spoke diagram to show how the 'Recursion OS' platform feeds into two distinct strategic paths.present_solution
82
The chart uses a horizontal bar format to represent the stage of development for various oncology and rare disease programs.present_framework
84
Includes a medical image (MRI) with annotations and a supporting expert quote.frame_problem
85
The slide uses a table to contrast the prevalence of CCM with established orphan disease products.size_opportunity
86
Includes a patient photo and source citations at the bottom.diagnose_problem
87
The slide uses a medical MRI image with annotations to illustrate the condition.present_solution
88
The slide is a scientific illustration of a cellular signaling pathway.establish_context
89
The slide uses a bar chart to demonstrate that the intervention (Statin-Enhanced Diet) actually worsens the condition (higher lesion count) compared to the contdiagnose_problem
90
The slide uses a before-after visual comparison of microscopy images to frame the problem/opportunity for ML-based analysis.illustrate_case
91
The slide contrasts human perception (Simvastatin looks like a rescue) with machine learning results (Cholecalciferol and REC-994 show rescue).illustrate_case
92
Slide 92 of a presentation deck.analyze_data
93
The slide uses a before-after-bridge structure to explain the therapeutic mechanism of REC-994 in the context of CCM.present_solution
94
The table compares Placebo against 50mg, 200mg, 400mg, and 800mg doses across various safety metrics.analyze_data
95
The slide outlines a randomized controlled trial structure with three arms (400mg, 200mg, placebo) followed by a 12-month treatment period.present_framework
97
Includes a patient photo and source citation.frame_problem
98
The slide uses a pie chart to segment the patient population and an MRI scan to illustrate the clinical problem.size_opportunity
99
The slide uses a combination of quantitative scatter plot data and qualitative imaging to demonstrate drug efficacy.illustrate_case
100
The slide uses a numbered process flow to explain the mechanism of action of a drug candidate.present_solution
101
The slide uses a split-screen layout to compare two different preclinical efficacy studies.analyze_data
102
Slide 102 from a presentation deck.summarize
103
The diagram uses a layered arrow approach to show cumulative advantages.compare_peers
104
The slide uses a process flow diagram to illustrate the clinical trial stages for Cohort A (Phase 2) and Cohort B (Phase 3).plan_implementation
106
The slide uses a medical image of polyps to illustrate the condition.establish_context
107
Includes a medical illustration of colonoscopy and a quote from a medical professional.diagnose_problem
108
The chart shows a 'rescue' effect where the drug moves the disease state (red) closer to the healthy state (green).illustrate_case
109
The slide uses a before-after framework to illustrate the mechanism of action (MoA) of a drug candidate.present_solution
110
The slide uses two distinct chart types (bar chart with error bars and dot plot with mean/SEM bars) to demonstrate efficacy across two metrics.analyze_data
111
Clinical: FAP context. Slide 111.summarize
112
The slide outlines a two-part clinical trial design (Part 1 and Part 2) with specific enrollment criteria and outcome measures.present_framework
114
Includes a testimonial/quote from a KOL regarding the lack of therapeutic relevance in HCC.frame_problem
115
The slide uses a table to quantify the addressable market and a callout box to link preclinical data to the study design.size_opportunity
116
The slide uses a heatmap to demonstrate biological similarity between drug dosage effects and specific gene regulation.analyze_data
117
The slide compares efficacy in mutant vs wildtype models using bar charts for tumor growth inhibition and Kaplan-Meier curves for progression-free survival.analyze_data
120
The slide uses a three-step process diagram to illustrate the biological mechanism of C. diff infection.diagnose_problem